Buprenorphine and Voxelotor: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Voxelotor
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking buprenorphine (like Belbuca, Suboxone, or Sublocade) together with voxelotor (Oxbryta). Voxelotor slows down the liver enzyme that normally breaks down buprenorphine. When that happens, more buprenorphine can build up in your body than expected.
Because buprenorphine is an opioid, higher levels can mean stronger and longer-lasting effects, like feeling very sleepy or having slowed, shallow breathing. That is why this pairing is taken seriously. The good news is that your care team can manage this by adjusting your buprenorphine dose and watching you more closely. Please don't change either medicine on your own. Just check in with your pharmacist or doctor.
Effect: Voxelotor inhibits CYP3A4, reducing buprenorphine metabolism and increasing buprenorphine plasma concentrations (increased exposure). This raises the risk of prolonged opioid effects, including sedation and respiratory depression.
- Direction: Increased buprenorphine effect (buprenorphine is the active agent, not a prodrug requiring activation here).
- Severity/Evidence: Major; probable substantiation. Onset unspecified.
- Management: If voxelotor is needed, consider reducing the buprenorphine dose until stable, monitor frequently for sedation/respiratory depression. On voxelotor discontinuation, anticipate a possible buprenorphine dose increase and watch for withdrawal. For subQ depot formulations, monitor for over-medication; use a formulation allowing precise titration if adjustment is needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because plasma buprenorphine levels rise when buprenorphine is taken alongside a CYP3A4 inhibitor, opioid effects such as respiratory depression may be extended. When a patient on buprenorphine needs to start a CYP3A4 inhibitor, one option is to lower the buprenorphine dose until drug effects stabilize while checking often for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is being stopped in a patient who is on buprenorphine, consider raising the buprenorphine dose until stable effects are reached and watch for indications of opioid withdrawal2. Should dose adjustment prove impossible once the CYP3A4 inhibitor is no longer present, move the patient back to a buprenorphine formulation that allows finer dose control. For patients switched from transmucosal buprenorphine given together with CYP3A4 inhibitors, confirm through monitoring that subQ buprenorphine delivers an adequate plasma buprenorphine level. For those already receiving subQ buprenorphine who then require a CYP3A4 inhibitor, monitor for indications of over-medication. If buprenorphine toxicity or overdose signs and symptoms appear yet the co-administered drug cannot be lowered or stopped, decrease the buprenorphine dose. When the available doses cannot deliver the intended dose, stop therapy and manage the patient with a buprenorphine formulation that supports more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what they typically do with this combination:
- Your buprenorphine dose may need to be adjusted and individualized while you are on voxelotor, and your team may monitor you more closely for excess sleepiness or slowed breathing.
- If voxelotor is later stopped, your buprenorphine dose may need to go back up, so your team will watch for signs of withdrawal.
- If you use a long-acting injectable buprenorphine, tell your team, since they may need a formulation that allows finer dose changes.
Call your prescriber or pharmacist right away if you notice unusual drowsiness, confusion, or slow or shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been demonstrated in trials involving transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Voxelotor together?
Voxelotor can raise buprenorphine levels and increase the risk of oversedation and slowed breathing, so your care team may lower and closely monitor your buprenorphine dose. Do not change either drug on your own, and report any excessive drowsiness or breathing trouble. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Voxelotor interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Voxelotor interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what they typically do with this combination: Your buprenorphine dose may need to be adjusted and individualized while you are on voxelotor, and your team may monitor you more closely for excess sleepiness or slowed breathing. If voxelotor is later stopped, your buprenorphine dose may need to go back up, so… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Voxelotor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Voxelotor
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist